Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to Calicheamicin (HY-19609). Inotuzumab ozogamicin and G544 bind human CD22 with similar affinities (Kd ~ 150 pM). Inotuzumab ozogamicin has demonstrated efficacy against CD22+ B-cell non-Hodgkins lymphoma. Inotuzumab ozogamicin can be used in the research of acute lymphoblastic leukemia[1][2][3].
Purity:
99.7
CAS Number:
[635715-01-4]
Target:
Antibody-Drug Conjugates (ADCs),CD22
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
